Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free MDCX Stock Alerts

Medicus Pharma (MDCX) Financials

Medicus Pharma logo
$0.37 -0.01 (-3.40%)
Closing price 04:00 PM Eastern
Extended Trading
$0.38 +0.00 (+0.67%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Medicus Pharma

Annual Income Statements for Medicus Pharma

This table shows Medicus Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.31 -11 -47
Consolidated Net Income / (Loss)		 -5.31 -11 -35
Net Income / (Loss) Continuing Operations		 -5.31 -11 -36
Total Pre-Tax Income 		-5.31 -11 -36
Total Operating Income		 -4.73 -11 -34
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 4.73 11 34
Selling, General & Admin Expense		 4.54 7.65 18
Research & Development Expense		 0.19 3.53 16
Total Other Income / (Expense), net		 -0.58 0.05 -1.32
Interest Expense		 - -0.03 0.22
Other Income / (Expense), net		 - 0.03 -1.10
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 -0.00
Basic Earnings per Share		 ($1.53) ($1.16) ($2.74)
Weighted Average Basic Shares Outstanding		 3.48M 9.62M 17.28M
Diluted Earnings per Share		 ($1.53) ($1.16) ($2.74)
Weighted Average Diluted Shares Outstanding		 3.48M 9.62M 17.28M
Weighted Average Basic & Diluted Shares Outstanding		 - 13.41M 39.36M

Quarterly Income Statements for Medicus Pharma

This table shows Medicus Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -1.67 -34 -9.04
Consolidated Net Income / (Loss)		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04
Net Income / (Loss) Continuing Operations		 -1.71 -3.63 -2.28 -3.51 -5.08 -6.14 -1.67 -23 -9.12
Total Pre-Tax Income 		-1.71 -3.63 -2.28 -3.51 -5.08 -6.14 -1.67 -23 -9.12
Total Operating Income		 -1.71 -3.55 -2.33 -3.59 -5.13 -6.02 -0.00 -23 -8.60
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.71 3.55 2.33 3.59 5.13 6.02 1.68 22 8.60
Selling, General & Admin Expense		 1.39 2.28 1.77 2.22 3.12 4.58 0.00 10 5.89
Research & Development Expense		 0.32 1.28 0.56 1.37 2.01 1.44 1.68 11 2.70
Total Other Income / (Expense), net		 0.00 -0.08 0.06 0.07 0.05 -0.12 0.01 -1.23 -0.52
Interest Expense		 - 0.08 -0.06 - 0.00 -0.04 -0.01 - 0.37
Interest & Investment Income		 0.00 - - - 0.02 - - - 0.06
Other Income / (Expense), net		 - - 0.00 - 0.02 -0.16 - - -0.20
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - 0.00 - 0.00 - - - -0.00
Basic Earnings per Share		 ($0.21) ($0.44) ($0.24) ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31)
Weighted Average Basic Shares Outstanding		 8.08M 8.17M 9.51M 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M
Diluted Earnings per Share		 ($0.21) ($0.44) ($0.24) ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31)
Weighted Average Diluted Shares Outstanding		 8.08M 8.17M 9.51M 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 13.41M 13.49M 17.82M 22.03M 39.36M 56.66M

Annual Cash Flow Statements for Medicus Pharma

This table details how cash moves in and out of Medicus Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.45 2.44 4.54
Net Cash From Operating Activities		 -4.16 -10 -23
Net Cash From Continuing Operating Activities		 -4.16 -10 -23
Net Income / (Loss) Continuing Operations		 -5.31 -11 -35
Consolidated Net Income / (Loss)		 -5.31 -11 -35
Non-Cash Adjustments To Reconcile Net Income		 0.68 0.88 12
Changes in Operating Assets and Liabilities, net		 0.47 0.03 0.57
Net Cash From Investing Activities		 0.00 0.00 -4.62
Net Cash From Continuing Investing Activities		 0.00 0.00 -4.62
Acquisitions		 - 0.00 -4.62
Net Cash From Financing Activities		 5.61 13 32
Net Cash From Continuing Financing Activities		 5.61 13 32
Repayment of Debt		 - 0.00 -7.53
Repurchase of Common Equity		 - 0.00 -0.65
Issuance of Debt		 0.50 5.17 12
Issuance of Common Equity		 0.00 7.52 18
Other Financing Activities, net		 5.11 0.00 10
Effect of Exchange Rate Changes		 - 0.00 -0.00
Cash Interest Paid		 0.00 0.04 0.22

Quarterly Cash Flow Statements for Medicus Pharma

This table details how cash moves in and out of Medicus Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.18 7.87 -3.10 -1.14 -0.18 5.69 3.95 -4.91 -2.34
Net Cash From Operating Activities		 -1.18 -2.78 -3.10 -3.19 -3.94 -5.47 -6.76 -6.61 -8.97
Net Cash From Continuing Operating Activities		 -1.18 -2.78 -3.10 -3.19 -3.94 -5.47 -1.80 -12 -8.97
Net Income / (Loss) Continuing Operations		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04
Consolidated Net Income / (Loss)		 -1.71 -3.63 -2.28 -3.54 -5.10 -6.18 -16 -8.18 -9.04
Non-Cash Adjustments To Reconcile Net Income		 0.07 0.70 0.03 0.08 0.11 0.48 15 -3.90 1.13
Changes in Operating Assets and Liabilities, net		 0.46 0.16 -0.85 0.26 1.05 0.23 -1.23 0.52 -1.06
Net Cash From Investing Activities		 0.00 - - - 0.00 - -4.62 - 0.00
Net Cash From Continuing Investing Activities		 0.00 - - - 0.00 - -4.62 - 0.00
Net Cash From Financing Activities		 0.00 11 - 2.05 3.76 11 10 6.65 6.83
Net Cash From Continuing Financing Activities		 0.00 11 - 2.05 3.76 11 10 6.65 6.83
Repayment of Debt		 0.00 - - - -0.03 -0.27 -5.48 -1.75 -3.18
Issuance of Common Equity		 0.00 5.47 - 2.05 3.78 6.01 - 8.43 10
Effect of Exchange Rate Changes		 - - - - - - - - -0.20
Cash Interest Paid		 - - - - 0.00 - - - 0.10

Annual Balance Sheets for Medicus Pharma

This table presents Medicus Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.89 5.65 10
Total Current Assets		 1.89 5.38 9.89
Cash & Equivalents		 1.72 4.16 8.71
Prepaid Expenses		 0.17 1.21 1.09
Other Current Assets		 - 0.00 0.10
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.27 0.17
Other Noncurrent Operating Assets		 0.00 0.27 0.17
Total Liabilities & Shareholders' Equity		 1.89 5.65 10
Total Liabilities		 0.78 2.51 10
Total Current Liabilities		 0.78 2.31 9.94
Short-Term Debt		 - 0.00 5.25
Accounts Payable		 0.21 1.28 3.44
Accrued Expenses		 0.40 0.76 1.00
Other Current Liabilities		 0.17 0.26 0.26
Total Noncurrent Liabilities		 0.00 0.21 0.09
Long-Term Debt		 - 0.00 0.03
Other Noncurrent Operating Liabilities		 0.00 0.21 0.06
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1.11 3.13 0.04
Total Preferred & Common Equity		 1.11 3.13 -0.07
Total Common Equity		 1.11 3.13 -0.07
Common Stock		 19 32 64
Retained Earnings		 -18 -29 -64
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 0.01
Other Equity Adjustments		 - 0.00 0.31
Noncontrolling Interest		 - 0.00 0.10

Quarterly Balance Sheets for Medicus Pharma

This table presents Medicus Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.66 12 9.98 7.43
Total Current Assets		 5.09 11 9.78 7.28
Cash & Equivalents		 3.98 9.67 8.66 6.37
Prepaid Expenses		 1.11 1.33 1.12 0.92
Other Current Assets		 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.57 0.94 0.20 0.14
Other Noncurrent Operating Assets		 0.57 0.94 0.20 0.14
Total Liabilities & Shareholders' Equity		 5.66 12 9.98 7.43
Total Liabilities		 3.51 8.69 11 6.00
Total Current Liabilities		 3.34 8.54 11 5.95
Short-Term Debt		 - 4.70 6.79 2.34
Accounts Payable		 2.04 1.77 2.03 2.28
Accrued Expenses		 1.06 1.83 1.56 1.04
Other Current Liabilities		 0.24 0.25 0.28 0.29
Total Noncurrent Liabilities		 0.17 0.14 0.10 0.05
Long-Term Debt		 - - - 0.02
Other Noncurrent Operating Liabilities		 0.17 0.14 0.10 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.15 3.25 -0.80 1.43
Total Preferred & Common Equity		 2.15 3.25 6.45 1.33
Total Common Equity		 2.15 3.25 6.45 1.33
Common Stock		 36 43 6.45 75
Retained Earnings		 -34 -40 -0.00 -73
Accumulated Other Comprehensive Income / (Loss)		 - - - -0.19
Other Equity Adjustments		 - - - 0.31
Noncontrolling Interest		 - - - 0.10

Annual Metrics And Ratios for Medicus Pharma

This table displays calculated financial ratios and metrics derived from Medicus Pharma's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 22,029,144.00
DEI Adjusted Shares Outstanding		 0.00 0.00 22,029,144.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -2.15
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -135.85% -217.83%
EBIT Growth		 0.00% -135.85% -217.83%
NOPAT Growth		 0.00% -136.39% -207.30%
Net Income Growth		 0.00% -109.90% -217.73%
EPS Growth		 0.00% 24.18% -136.21%
Operating Cash Flow Growth		 0.00% -146.43% -122.27%
Free Cash Flow Firm Growth		 0.00% 0.00% -192.84%
Invested Capital Growth		 0.00% -69.38% -229.88%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -140.74%
EBIT Q/Q Growth		 0.00% 0.00% -140.74%
NOPAT Q/Q Growth		 0.00% 0.00% -133.30%
Net Income Q/Q Growth		 0.00% 0.00% -15.09%
EPS Q/Q Growth		 0.00% 0.00% -22.32%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -17.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% -28.09%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.23% 99.35%
Interest Burden Percent		 112.36% 99.77% 100.63%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -478.18% -525.44% -2,234.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -478.18% -525.44% -2,160.94%
Return on Equity Simple (ROE_SIMPLE)		 -478.18% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.31 -7.83 -24
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -116.55% -113.16% -299.89%
Return On Investment Capital (ROIC_SIMPLE)		 -297.90% -249.68% -453.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.73 -11 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.73 -11 -35
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 7.46 0.00
Price to Tangible Book Value (P/TBV)		 0.00 7.46 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 141.28
Long-Term Debt to Equity		 0.00 0.00 0.69
Financial Leverage		 -1.55 -1.39 -2.40
Leverage Ratio		 1.70 1.78 4.95
Compound Leverage Factor		 1.91 1.77 4.98
Debt to Total Capital		 0.00% 0.00% 99.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 98.81%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 1.98%
Common Equity to Total Capital		 100.00% 100.00% -1.27%
Debt to EBITDA		 0.00 0.00 -0.15
Net Debt to EBITDA		 0.00 0.00 0.10
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.22
Net Debt to NOPAT		 0.00 0.00 0.14
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.00 -7.45 -19.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 3.31%
Liquidity Ratios		 - - -
Current Ratio		 2.42 2.33 1.00
Quick Ratio		 2.20 1.81 0.88
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.40 -22
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -97.51
Operating Cash Flow to Interest Expense		 0.00 0.00 -102.42
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -102.42
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -0.61 -1.03 -3.40
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.42 -2.37
Enterprise Value (EV)		 0.00 19 23
Market Capitalization		 0.00 23 26
Book Value per Share		 $0.32 $0.33 $0.00
Tangible Book Value per Share		 $0.32 $0.33 $0.00
Total Capital		 1.11 3.13 5.31
Total Debt		 0.00 0.00 5.27
Total Long-Term Debt		 0.00 0.00 0.03
Net Debt		 -1.72 -4.16 -3.43
Capital Expenditures (CapEx)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.61 -1.09 -3.51
Debt-free Net Working Capital (DFNWC)		 1.11 3.07 5.20
Net Working Capital (NWC)		 1.11 3.07 -0.05
Net Nonoperating Expense (NNE)		 2.00 3.33 11
Net Nonoperating Obligations (NNO)		 -1.72 -4.16 -3.43
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.16) ($2.74)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 9.62M 17.28M
Adjusted Diluted Earnings per Share		 $0.00 ($1.16) ($2.74)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 9.62M 17.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.41M 39.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.31 -7.83 -24
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 -159.43
NOPAT to Interest Expense		 0.00 0.00 -108.15
EBIT Less CapEx to Interest Expense		 0.00 0.00 -159.43
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -108.15
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -1.84%

Quarterly Metrics And Ratios for Medicus Pharma

This table displays calculated financial ratios and metrics derived from Medicus Pharma's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 13,414,801.00 13,494,861.00 17,816,266.00 22,029,144.00 39,362,109.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 13,414,801.00 13,494,861.00 17,816,266.00 22,029,144.00 39,362,109.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 -0.38 -0.46 -0.09 -1.56 -0.23
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -73.79% 100.00% -547.53% -72.49%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -73.79% 100.00% -547.53% -72.49%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -200.25% -69.28% 100.00% -547.53% -67.71%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -198.85% -70.01% -601.32% -131.43% -77.22%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -100.00% 2.27% -366.67% -185.19% 26.19%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -234.85% -96.95% -117.85% -107.08% -127.60%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -201.10%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -229.88% -40.22%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.31% -20.48% 100.00% -154,779,400.00% 62.09%
EBIT Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.31% -20.48% 100.00% -154,779,400.00% 62.09%
NOPAT Q/Q Growth		 0.00% -108.15% 34.32% -53.60% -42.97% -17.36% 100.00% -154,779,400.00% 62.97%
Net Income Q/Q Growth		 0.00% -112.78% 37.27% -55.20% -44.28% -21.04% -158.76% 48.79% -10.48%
EPS Q/Q Growth		 0.00% -109.52% 45.45% -12.50% -55.56% -2.38% -160.47% 31.25% 59.74%
Operating Cash Flow Q/Q Growth		 0.00% -135.93% -11.72% -2.89% -23.48% -38.77% -23.57% 2.20% -35.72%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -42.02% 206.48% -623.63% 61.97%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -78.21% 6.22% -54.09% -28.09% 24.25%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.72% 100.47% 100.65% 955.13% 35.95% 99.15%
Interest Burden Percent		 100.00% 102.22% 97.62% 97.93% 99.53% 99.35% 11,154,773.33% 98.06% 103.61%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -525.44% -677.54% -526.17% 3,826.16% -2,234.82% -2,203.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -525.44% -677.54% -526.17% -30,660.32% -2,160.94% -2,140.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.20 -2.49 -1.63 -2.51 -3.59 -4.21 -0.00 -16 -6.02
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% -24.66% -76.03% -79.07% -1,730.69% 212.35% -75.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -80.07% -167.09% -52.98% 0.00% -306.14% -158.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.71 -3.55 -2.33 -3.59 -5.10 -6.18 -0.00 -23 -8.80
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.71 -3.55 -2.33 -3.59 -5.10 -6.18 -0.00 -23 -8.80
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 7.46 21.20 13.15 6.69 0.00 10.23
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 7.46 21.20 13.15 6.69 0.00 10.23
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 1.45 -8.43 141.28 1.66
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.01
Financial Leverage		 0.00 0.00 0.00 -1.33 -1.85 -1.53 2.29 -2.40 -2.23
Leverage Ratio		 0.00 0.00 0.00 1.78 2.63 3.67 -12.40 4.95 3.66
Compound Leverage Factor		 0.00 0.00 0.00 1.74 2.62 3.65 -1,382,779.60 4.86 3.79
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 59.13% 113.46% 99.30% 62.35%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 59.13% 113.46% 98.81% 61.80%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.49% 0.55%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.98% 2.69%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 40.87% 107.84% -1.27% 34.96%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.28 -0.46 -0.15 -0.06
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.29 0.13 0.10 0.10
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.39 -0.66 -0.22 -0.09
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.42 0.18 0.14 0.15
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -3.03 -3.24 -3.22 2.29 -14.99 -16.17
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 901.33% 3.31% 2.85%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 2.33 1.53 1.29 0.92 1.00 1.22
Quick Ratio		 0.00 0.00 0.00 1.81 1.19 1.13 0.81 0.88 1.07
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -1.75 -2.49 2.65 -14 -5.28
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -14.09
Operating Cash Flow to Interest Expense		 0.00 -35.14 0.00 0.00 0.00 0.00 0.00 0.00 -23.94
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -35.14 0.00 0.00 0.00 0.00 0.00 0.00 -23.94
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -1.03 -1.83 -1.72 -2.65 -3.40 -2.57
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -1.83 -1.72 -2.65 -2.37 -0.74
Enterprise Value (EV)		 0.00 0.00 0.00 19 42 38 41 23 9.66
Market Capitalization		 32 27 33 23 46 43 43 26 14
Book Value per Share		 $0.00 $0.00 $0.00 $0.33 $0.16 $0.24 $0.36 $0.00 $0.03
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.33 $0.16 $0.24 $0.36 $0.00 $0.03
Total Capital		 0.00 0.00 0.00 3.13 2.15 7.95 5.98 5.31 3.79
Total Debt		 0.00 0.00 0.00 0.00 0.00 4.70 6.79 5.27 2.36
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.02
Net Debt		 0.00 0.00 0.00 -4.16 -3.98 -4.97 -1.88 -3.43 -4.00
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -1.09 -2.23 -2.52 -2.75 -3.51 -2.69
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 3.07 1.75 7.15 5.91 5.20 3.67
Net Working Capital (NWC)		 0.00 0.00 0.00 3.07 1.75 2.45 -0.88 -0.05 1.33
Net Nonoperating Expense (NNE)		 0.51 1.15 0.64 1.03 1.51 1.96 16 -8.07 3.02
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -4.16 -3.98 -4.97 -1.85 -3.43 -4.00
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.27) ($0.42) ($0.43) ($1.12) ($0.77) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 9.62M 12.24M 14.28M 18.63M 17.28M 29.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 13.41M 13.49M 17.82M 22.03M 39.36M 56.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.20 -2.49 -1.63 -2.51 -3.59 -4.21 -0.00 -16 -6.02
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 -44.97 0.00 0.00 0.00 0.00 0.00 0.00 -23.49
NOPAT to Interest Expense		 0.00 -31.48 0.00 0.00 0.00 0.00 0.00 0.00 -16.06
EBIT Less CapEx to Interest Expense		 0.00 -44.97 0.00 0.00 0.00 0.00 0.00 0.00 -23.49
NOPAT Less CapEx to Interest Expense		 0.00 -31.48 0.00 0.00 0.00 0.00 0.00 0.00 -16.06
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.84% 0.00%

Financials Breakdown Chart

Key Financial Trends

Medicus Pharma Ltd. (NASDAQ: MDCX) remains an early-stage, pre-revenue biotech with heavy cash burn and a reliance on external financing. Over the last four years, the company has continued to spend aggressively on research and development and SG&A while generating no product revenue. That combination has produced persistent net losses and negative operating cash flow, even though the balance sheet still shows a meaningful cash position after recent equity raises.

  • Cash balance improved versus year-end 2024: Medicus ended Q1 2026 with $6.4 million in cash and equivalents, up from $3.98 million at Q1 2025, helped by recent financing activity.
  • Equity financing continues to support liquidity: The company raised about $10.0 million from common equity in Q1 2026, following additional equity issuance in prior quarters.
  • Balance sheet leverage appears limited: Total debt was only about $2.36 million at Q1 2026, with long-term debt just $21 thousand, suggesting the capital structure is not yet heavily burdened by borrowings.
  • Operating cash burn narrowed quarter over quarter: Cash used in operations was $9.0 million in Q1 2026, less negative than Q4 2025’s $11.6 million, though still substantial.
  • No revenue yet: Revenue was $0 in every reported quarter provided, so the story remains entirely about clinical development and financing rather than commercial execution.
  • Share count has risen materially: Dilution has been significant, with weighted average basic shares increasing from 8.1 million in Q1 2024 to 29.5 million in Q1 2026, reflecting repeated equity raises.
  • Quarterly losses remain large: Q1 2026 net loss was $9.0 million, following a $8.2 million loss in Q4 2025 and $16.0 million loss in Q3 2025.
  • Persistent negative operating cash flow: Medicus has posted negative operating cash flow in every quarter shown, including -$3.9 million in Q1 2025, -$5.5 million in Q2 2025, -$6.8 million in Q3 2025, -$6.6 million in Q4 2025, and -$9.0 million in Q1 2026.
  • Annual operating expenses have risen sharply: Q1 2026 operating expenses totaled $8.6 million, versus $5.1 million in Q1 2025 and $3.6 million in Q4 2024, showing a higher cost base.
  • Working capital cushion is still thin: At Q1 2026, current assets were $7.3 million against current liabilities of $6.0 million, leaving only a modest current ratio and limited room for error if financing slows.

Bottom line: Medicus Pharma is still in a cash-consuming development phase. The company has enough liquidity for now and continues to access equity markets, but the combination of zero revenue, widening operating losses, and recurring dilution makes the investment case highly dependent on future clinical or financing milestones.

07/23/26 12:15 AM ETAI Generated. May Contain Errors.

Medicus Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medicus Pharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Medicus Pharma's net income appears to be on an upward trend, with a most recent value of -$35.44 million in 2025, rising from -$5.31 million in 2023. The previous period was -$11.16 million in 2024. See Medicus Pharma's forecast for analyst expectations on what's next for the company.

Medicus Pharma's total operating income in 2025 was -$34.36 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $34.36 million

Over the last 2 years, Medicus Pharma's total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

Medicus Pharma's total liabilities were at $10.02 million at the end of 2025, a 299.0% increase from 2024, and a 1,182.5% increase since 2023.

In the past 2 years, Medicus Pharma's cash and equivalents has ranged from $1.72 million in 2023 to $8.71 million in 2025, and is currently $8.71 million as of their latest financial filing in 2025.

Over the last 2 years, Medicus Pharma's book value per share changed from 0.32 in 2023 to 0.00 in 2025, a change of -101.0%.


Related Companies

Financial statements for NASDAQ:MDCX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel